The Parexel Podcast | Episode 13: The New Pragmatism: Clinical Trials, Investment and Regulations Post-COVID-19

Once the COVID-19 pandemic passes or is contained, the world will look and work very differently. The biopharmaceutical industry is no exception. In this podcast, Peyton Howell, Chief Operating and Growth Officer, talks with Paul Bridges, Head of Consulting, and Sheela Hegde, a Partner with Parexel’s Health Advances subsidiary, about the regulatory, investing and clinical development changes that are most likely here to stay – The New Pragmatism. After listening, you can read more about Paul and Sheela’s perspective in this article: https://regulatory-access.parexel.com/parexels-covid-19-expert-content/covid-19-and-the-new-pragmatism

Return to Insights Center

Related Insights

Related Insights

Blog

What COVID Taught Us About Focus, Innovation, and Leadership

Sep 24, 2021

Blog

Population diversity: important considerations in vaccine development

Jun 14, 2023

Video

How to transition existing trials under EU-CTR

Feb 1, 2023

Whitepaper

Master Protocols from Design to Delivery

Sep 30, 2021

Podcast

Enabling Successful Sites, Episode 2: Empowering Sites to be More Inclusive Through Cultural Sensitivity Training

Jun 28, 2024

Article

Part 1 - Preparing for a Risk-Based Future: What ICH Revisions Mean for Clinical Trial Design and Conduct

Sep 14, 2021

Show more